Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totaling 506,729 shares, a growth of 7,428.3% from the June 30th total of 6,731 shares. Based on an average trading volume of 2,149,123 shares, the days-to-cover ratio is currently 0.2 days. Currently, 16.8% of the shares of the stock are short sold.

Exicure Trading Up 2.9%

XCUR stock traded up $0.05 during trading on Friday, hitting $1.76. The company had a trading volume of 52,895 shares, compared to its average volume of 193,801. The firm has a market capitalization of $11.21 million, a price-to-earnings ratio of -1.14 and a beta of 3.61. Exicure has a fifty-two week low of $1.43 and a fifty-two week high of $9.48. The business has a 50 day moving average of $2.40 and a 200 day moving average of $3.62.

Exicure (NASDAQ:XCUR) last announced its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.31.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Exicure presently has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.